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Available online 13 May 2016Dravet syndrome is a devastating genetic brain disorder caused by heterozygous loss-of-functionmutation in the
voltage-gated sodium channel gene SCN1A. There are currently no treatments, but the upregulation of SCN1A
healthy allele represents an appealing therapeutic strategy. In this study we identiﬁed a novel, evolutionary con-
served mechanism controlling the expression of SCN1A that is mediated by an antisense non-coding RNA
(SCN1ANAT). Using oligonucleotide-based compounds (AntagoNATs) targeting SCN1ANAT we were able to in-
duce speciﬁc upregulation of SCN1A both in vitro and in vivo, in the brain of Dravet knock-in mouse model and
a non-human primate. AntagoNAT-mediated upregulation of Scn1a in postnatal Dravet mice led to signiﬁcant
improvements in seizure phenotype and excitability of hippocampal interneurons. These results further eluci-
date the pathophysiology of Dravet syndrome and outline a possible new approach for the treatment of this
and other genetic disorders with similar etiology.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Currently there is no treatment for many genetic disorders associated
with loss-of-function mutations in one of the copies of a single gene
(haploinsufﬁciency). Dravet syndrome (DS) is one of such disorders. DS
is caused by heterozygous mutations in the SCN1A gene coding for the
pore-forming alpha subunit of the voltage-gated sodium channel Nav1.1.
Clinically, DS is characterized by seizure onset in the ﬁrst year of life, fe-
brile seizures, prolonged seizures resistant to anticonvulsants, progressive
psychomotor retardation and high incidence of sudden unexpected death
(Dravet, 2011). Importantly, inmost studiedDScasesnomutantprotein is
produced and the characteristics of the Nav1.1-mediated sodium current
are not signiﬁcantly altered. However, the amplitude of the sodiumhlestedt).
. This is an open access article undercurrent and SCN1A mRNA and protein levels are diminished (Sugawara
et al., 2003; Vanoye et al., 2006; Ohmori et al., 2006; Bechi et al., 2011).
Although signiﬁcant insights into DS disease mechanism have been
achieved in recent years, it is still not clear if major manifestations of the
disease are caused by disturbances in embryonic development or by per-
sistent SCN1A deﬁciency in later life. It is also not known if increasing
SCN1A expression after birth, when most genetic diseases are diagnosed,
would alter the disease phenotype. Arguably the therapeutically required
increase in SCN1A should not be very high, because just doubling the ex-
pression in haploinsufﬁcient cells would restore the normal levels of the
protein. In addition, excessive sodium currents, for example in cases of
genomic duplications of sodium channel genes, also lead to seizures
(Goeggel Simonetti et al., 2012; Yoshitomi et al., 2015).
To explore the effects of postnatal upregulation of SCN1A expression
in Dravet syndrome, we took advantage of a novel long non-coding
RNA(lncRNA)-based mechanism of gene regulation which, as wethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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is mediated by a lncRNA from the natural antisense transcript (NAT)
class, which we named SCN1ANAT. Similar to other NATs (Katayama
et al., 2005; Derrien et al., 2012), SCN1ANAT is a multi-exonic lncRNA
transcribed from the opposite strand of the SCN1A gene (Fig. 1).
SCN1ANAT shares small overlaps with the SCN1A coding sequences in
both human and mouse genomes. NATs are known to function as ﬁne
modulators of on-going transcription, affecting a single gene or a small
subset of related genes (Wahlestedt, 2013; Nakagawa and Kageyama,
2014; Zhao et al., 2010; Davidovich et al., 2013; Yu et al., 2015). The
mechanisms of this gene-speciﬁc regulation likely involve tethering/
scaffolding of general-purpose epigenetic complexes at a particular
gene locus (Magistri et al., 2012; Khalil et al., 2009; Peschansky and
Wahlestedt, 2014). Methylation and other modiﬁcations of histones
and DNA deposited by these complexes trigger chromatin compaction
and transcriptional inhibition. Depleting NAT molecules or blocking
their interaction with epigenetic complexes and DNA, or in essence
inhibiting the inhibitor, leads to upregulation of their target protein cod-
ing genes (Katayama et al., 2005; Meng et al., 2015; Chung et al., 2011;
Halley et al., 2014;Modarresi et al., 2012;Matsui et al., 2013; Yamanaka
et al., 2015). Several epigenetic protein complexes have been shown to
depend on NATs for their speciﬁcity (Nakagawa and Kageyama, 2014,
Khalil et al., 2009; Kotake et al., 2011; Zhao et al., 2010). For example,Fig. 1. SCN1A and SCN1ANAT coding regions are localized on opposite chromosomal strands in
insets: empty boxes — SCN1ANAT exons; ﬁlled boxes — SCN1A exons; grey lines — compleme
1901 — positions of sequences complementary to respective AntagoNATs.interfering with BDNF NAT function using synthetic oligonucleotide-
based compounds (AntagoNATs) resulted in reduced levels ofmethylat-
ed lysine 27 in histone 3 in BDNF locus, reduced binding of a PRC2 com-
ponent at the BDNF promoter, and increased expression of biologically
active BDNF protein (Modarresi et al., 2012). Furthermore, blocking
APOA1NAT caused signiﬁcant changes in histoneH3methylation levels
and affected expression of several genes in the APOA1 cluster (Halley et
al., 2014). In another example, a NAT from Lrp1 locus was shown to di-
rectly inhibit the activity of Hmgb2, a protein known to enhance the
transcription of Lrp1. Oligonucleotides targeting Lrp1NAT lifted its inhib-
itory interaction with Hmgb2 protein and increased Lrp1 expression
(Yamanaka et al., 2015). Such DNA-level mechanisms enable NATs, fre-
quently present in very low copy numbers, to efﬁciently control tran-
scription at a given locus. As a consequence of their mechanism of
action, the inhibitory activity of NATs is highly speciﬁc: it is limited to par-
ticular genes and engages only in cell populations that normally express
their target coding genes (Magistri et al., 2012, Halley et al., 2014;
Modarresi et al., 2012). Overall, NAT-mediated regulation is likely more
suited to cases of haploinsufﬁciency than viral gene transfer, which
often induces signiﬁcant overexpression, is only partially responsive to
endogenous controls, and hasmultiple technical and regulatory problems
in the clinic. NAT-mediated regulation is present inmany gene loci and is
potentially applicable to the treatment of multiple genetic disordershuman andmouse genomes. (a) Human chromosome 2. (b)Mouse chromosome 2. In the
ntary chromosomal strands; angled arrows — direction of transcription; CUR-1916, CUR-
259J. Hsiao et al. / EBioMedicine 9 (2016) 257–277(Wahlestedt, 2013). Given these attributes, NATs represent attractive tar-
gets for multiple diseases requiring protein upregulation, including DS.
2. Materials and Methods
2.1. Cell Lines
Human neuroblastoma cell line SK-N-AS (ATCC # CRL-2137™), Afri-
can green monkey kidney epithelial cell line Vero 76 (ATCC # CRL-1587
™), embryonic ﬁbroblasts from the NIH/Swissmouse 3T3 (ATCC # CRL-
1658™) and brain neuroblastoma line from strain A albino mouse
Neuro2A (ATCC # CCL-131™) were obtained from American Type Cul-
ture Collection (USA). SK-N-AS cells were cultured in DMEM with 10%
FBS and 1% of penicillin/streptomycin. Vero76 cells were cultured in
DMEM with 5% FBS and 1% of penicillin/streptomycin. 3T3 cells were
cultured in Dulbecco's Modiﬁed Eagle's Medium with 10% FBS and 1%
of penicillin/streptomycin. Neuro-2A cells were cultured in Eagle's Min-
imum Essential Medium with 10% FBS and 1% of penicillin/streptomy-
cin. Experiments were performed within the ﬁrst 15 passages after
receipt form ATCC.
2.2. Introduction of Dravet Fibroblasts Into Culture
The skin biopsies for ﬁbroblast lines D-01 to D-04 were collected at
Surgery Center of Weston (Ft. Lauderdale, FL). All research subjects
have signed informed consent forms. One skin biopsy per patient
(~1 cm3) was taken from the buttocks and placed in DMEM/F-12
(Ham) 1:1 media with 1% of penicillin/streptomycin. The skin was sep-
arated from subcutaneous fat, cut into pieces smaller than 1 mm3,
aliquoted into 6 tubes each containing 6 ml of DMEM/F-12 (Ham) 1:1
media with 1% of penicillin/streptomycin and 4 mg of collagenase and
placed in a cell culture incubator. Twenty hours later the cells from1
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CUR-1837each tube were centrifuged, the pellet resuspended in 5 ml of DMEM/
F-12 (Ham) 1:1 media with 20% fetal bovine serum and 1% penicillin/
streptomycin (growth media) and plated in a 6-well plate. Twenty
four hours later the media was discarded and fresh growth media was
added to each well. When the cells reached 80–90% conﬂuency, the
cells from each well were trypsinized and transferred to a T25 ﬂask.
When the cells reached conﬂuence in the T25 ﬂasks, all cells from one
biopsy were pooled and seeded in 4xT75 ﬂasks. The cells were main-
tained with weekly 1:2–1:3 splits. All experiments were done with
cells from passages 4–20.
2.3. AntagoNAT Transfection
Cells were grown in appropriate growth media at 37 °C and 5% CO2.
One day before transfection the cells were replated at the density of
1.5 × 105/ml into 6 well plates and incubated at 37 °C and 5% CO2. On
the day of the transfection the media in the 6 well plates was changed
to fresh growth media. All AntagoNAT sequences were tested against
human genome and only ones with a single hit were chosen for extend-
ed investigation (sequences in table below). Lyophilized AntagoNATs
synthesized by IDT were diluted to the concentration of 20 μM. Two μl
of this solution were incubated with 400 μl of Opti-MEM media
(Gibco, USA) and 4 μl of Lipofectamine 2000 (Invitrogen, USA) at
room temperature for 20 min and applied to each well of the 6 well
plates with cells. Similar mixture including 2 μl of water instead of the
AntagoNAT solution was used for the mock-transfected controls. After
3–18 h of incubation at 7 °C and 5% CO2 the media was changed to
fresh growth media. Forty eight hours after addition of AntagoNATs
the media was removed and RNA was extracted from the cells using
SV Total RNA Isolation System from Promega or RNeasy Total RNA Iso-
lation kit from Qiagen (cat# 74181) following the manufacturers'
instructions.T*C*G* G*T*G* T*C*C* A*C*T* C*T*G* G*C*A* G*T
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rCrUrA rCrUrA rArArG rUrCrU rUrCrC rGrUrG rUrUrU rArAA T
rUrCrA rCrArA rArUrU rCrArG rArUrC rArCrC rCrArU rCrUrU rCrUrA
rGrArA rGrArU rGrGrG rUrGrA rUrCrU rGrArA rUrUrU rGrUG A
+G*+T*GGTA+T*AGGAA+C*+T*+G
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(continued on next page)
34 +G*+C*CAGT*C*A+C*AAA+T*+T*+C
35 +C*+A*CAAATTCAGA+T*+C*+A
36 mG*mG*mU*A*mU*A*G*G*mA*A*C*mU*G*G*mC*A*G*mC*A*G*mU*G*mU*mU*mG
37 mU*mG*mG*T*A*mU*A*G*mG*A*A*mC*T*G*G*mC*A*G*C*mA*mG*mU
38 mG*G*T*A*mU*A*G*G*A*A*mC*T*G*G*mC*A*G*mC*A*G*T*G*T*T*mG
39 mA*mA*G*mC*G*G*mU*A*T*A*G*G*A*A*mC*T*G*G*mC*A*G*mC*A*mG
40 G*T*G*G*C*A*T*A*G*G*G*A*C*G*G*G*C*A*G*C*A
CUR-1916 mG*mA*mG*C*C*A*G*mU*C*A*mC*A*A*A*mU*T*C*A*G*mA*T*C*A*mC*mC*mC
42 mA*A*mU*G*G*G*A*G*A*A*mC*mU*mU*G*A*G*A*G*mC*mA*mA
43 G*T*G*GAC*AGGAT*GCAC*AAAGG*A
44 mG*TGACmU*GTGCCmC*ATTGCTmG
45 mG*ACAAmC*CTTGmC*AGCCAmC*TGAmU*GATGmA
46 T*G*G*T*A*T*A*G*G*A*A*C*T*G*G*C*A*G*C*A
47 mU*mG*G*mU*A*mU*A*G*G*A*A*mC*T*G*G*mC*A*mG*mC*mA
48 mC*mC*A*G*T*mC*A*C*A*A*A*mU*T*mC*A*G*A*mU*mC*mA
49 mU*mG*G mU*A mU*A G G A A mC*T G G mC*AmG*mC*mA
50 mA*mG*C*C*A*G*mU*C*A*mC*A*A*A*mU*T*C*A*G*mA*T*C*A*mC*mC*mC
51 mG*mC*C*A*G*mU*C*A*mC*A*A*A*mU*T*C*mA*mG
52 mG*mC*C*A*G*mU*C*A*mC*A*A*A*mU*mU*mC
53 +G*+C*C*A*G*mU*C*A*mC*A*A*mA*mU*+T*+C
54 +G*C*C*A*G*+T*C*A*+C*A*A*A*T *+T*+C
55 +G*+C*mC*A*G*mU*C*A*mC*A*mA*+A*+T
CUR-1945 +G*+C*C*A*G*T*C*A*C*A*+A*+A*+T
57 +G*C*C*A*G*T*C*A*+C*+A*+A
58 +G*+C*C*A*G*T*C*A*C*+A*+A*+A
59 +A*+T*T*G*A*G*C*C*A*+G*+T*+C
60 TCGACTTTGAAAA
61 CCTCTCCACGCGCAGTACATT
62 G*T*A* G*C*A* C*T*G* T*G*G* A*C*A* T*C*G* G*C
63 G*T*A* G*A*A* G*A*A* C*A*G* C*C*C* G*T*A* G*T*G
64 G*T*C* C*A*A* T*C*A* T*A*C* A*G*C* A*G*A* A
65 G*T*G* A*C*T* G*T*A* C*C*A* A*T*T* G*C*T* G*T
66 A*C*T* T*C*T* T*C*C* A*C*T* C*C*T* T*C*C* T
67 G*A*T* G*T*C* C*C*T* T*C*C* T*G*C* G*T*T* G*T
68 T*G*T* G*G*A* T*G*C* T*G*G* G*T*G* T*C*T* C*T*C
69 T*C*C* C*A*G* T*G*A* C*T*C* C*C*G* A*T*G* C*T
70 A*G*T* C*T*C* A*G*T* T*G*T* C*A*G* T*A*C* C*T*C
71 T*C*G*G*A*T*C*A*T*C*A*G*G*G*T*T*G*T*A*G*T
72 G*T*G*G*T*A*T*A*G*G*A*A*C*T*G*G*C*A*G*C*A
73 +G*+T*A*T*A*G*G*A*A*C*T*G*+G*+C*+A
74 +G*+T*G*G*T*A*+T*A*G*G*A*A*+C*+T*+G
75 mG*mU*mG*G*mU*A*mU*A*G*G*A*A*mC*T*G*G*mC*A*mG*mC*mA
76 rArUrU rUrArA rArCrA rCrGrG rArArG rArCrU rUrUrA rGrUrA rGrUrG
rCrUrA rCrUrA rArArG rUrCrU rUrCrC rGrUrG rUrUrU rArAA T
77 +G*+T*GGTA+T*AGGAA+C*+T*+G
78 mG*mU*mG*G mU*A mU*A G G A A mC*T G G mC*AmG*mC*mA
79 mG*mG*mU*A*mU*A*G*G*mA*A*C*mU*G*G*mC*A*G*mC*A*G*mU*G*mU*mU*mG
80 mU*mG*mG*T*A*mU*A*G*mG*A*A*mC*T*G*G*mC*A*G*C*mA*mG*mU
81 mG*G*T*A*mU*A*G*G*A*A*mC*T*G*G*mC*A*G*mC*A*G*T*G*T*T*mG
82 mA*mA*G*mC*G*G*mU*A*T*A*G*G*A*A*mC*T*G*G*mC*A*G*mC*A*mG
83 G*T*G*G*C*A*T*A*G*G*G*A*C*G*G*G*C*A*G*C*A
CUR-1901 mG*mU*mG*G*mC*A*mU*A*G*mG*G*A*mC*G*G*G*mC*A*mG*mC*mA
85 mA*mC*mA*mA*mG*mU*G*G*C*A*T*A*G*G*G*A*C*G*G*mG*mC*mA*mG*mC*mA
86 mA*mC*A*A*G*mU*G*G*mC*A*T*A*mG*G*G*A*mC*G*G*G*mC*A*G*mC*mA
87 mA*A*G*mU*G*G*mC*A*mU*A*G*mG*G*A*mC*G*G*G*mC*A*G*mC*A*G*mU
88 mA*mA*mG*mU*mG*G*C*A*T*A*G*G*G*A*C*G*G*G*C*A*mG*mC*mA*mG*mU
89 G*T*G*ACTGTGCCCATTG*C*T*G
90 G*C*C*ACTT*GATGAT*CTA*A*A*C
CUR-1924 G*T*G*GAC*AGGAT*GCAC*AAAGG*A
92 mG*TGACmU*GTGCCmC*ATTGCTmG
93 mG*TGACTGTGCCCATTGCTmG
94 mC*CTCmU*TTCmU*GGCmC*TTGmC*TTmC
95 mG*ACAAmC*CTTGmC*AGCCAmC*TGAmU*GATGmA
96 T*G*G*T*A*T*A*G*G*A*A*C*T*G*G*C*A*G*C*A
97 mU*mG*G*mU*A*mU*A*G*G*A*A*mC*T*G*G*mC*A*mG*mC*mA
CUR-1462 mC*mC*mU*mA*mU*mC*T*T*T*C*C*C*C*C*C*C*C*T*mA*mC*mC*mU*mU*mU
* — phosphorothioate bond, m — 2′OMethyl modiﬁcation, + — LNA modiﬁcation, r — ribonucleotide.
(continued)
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2.4.1. RNA Extraction
Cultured cells were lysed inside the plates using SV total RNA kit
(Promega, WI USA). Mouse and monkey tissues were weighed and up
to 30 mg per sample were placed in 2 ml lysis matrix D tubes (MP Bio-
medicals, CA USA). The tissues were homogenized in RLT buffer(Qiagen, USA) using an MP FastPrep24 homogenizer (MP Biomedicals,
CA USA). Cell or tissue lysates were centrifuged to remove debris and
loaded onto nucleic acid-binding columns from respective RNA extrac-
tion kits. After several washes the bound RNA was subjected to DNAse
treatment directly on the column and then the total RNA was eluted
in DNAse/RNAse free water. RNA concentration was determined using
Multiskan spectrophotometer (Thermo Scientiﬁc, USA).
261J. Hsiao et al. / EBioMedicine 9 (2016) 257–2772.4.2. Reverse Transcription
100–500 ng of total RNAwas used per reverse transcription reaction.
The complementary DNAs were synthesized using High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, USA) or SuperScript Vilo
cDNA Synthesis Kit (Life Technologies) according to manufacturers'
protocols.
2.4.3. Quantitative Real Time PCR
cDNA was PCR ampliﬁed using TaqMan Fast Advance Master
Mix and TaqMan® Gene Expression Assays labeled with FAM
(Hs00374696_m1 speciﬁc for human or Mm00450580_m1 assay
speciﬁc for mouse Scn1a RNA; assays for human SCN2A —
Hs00221379_m1, SCN3A — Hs00366902_m1, SCN5A —
Hs00165693_m1, SCN7A — Hs00161546_m1, SCN8A —
Hs00274075_m1, SCN9A — Hs00161567_m1, mouse SCN9A —
Mm00405762_S1, custom assay for human SCN1ANAT — context se-
quence GGAAACACCACAGCATAGTGATTAG, assay for mouse Scn1aNAT
Mm01329045_mH) in a StepOne Plus analyzer (all from Applied
Biosystems, USA). For mouse Scn1aNAT assay RT was conducted with
sequence-speciﬁc primers (sequences shown below, synthesized by
IDT Inc.). The levels of 18S rRNA were estimated as an internal control,
using a TaqMan® Gene Expression Control labeled with VIC
(Mm03928990_g1 for mouse, Hs99999901_s1 for human and monkey,
all from Applied Biosystems, USA). The analysis of the data was done
using Excel software.
2.4.4. Quantitative Real Time PCR for Mutant and WT Alleles
Custommutant and wild type allele assays for D-00 and D-02muta-
tions were manufactured by Thermo Fisher Scientiﬁc. Copy numbers
were estimated using calibration standards synthesized by IDT Inc.
(sequences shown below).
2.5. Immunohistochemistry
Cells were grown in 24 well plates and treated with AntagoNATs as
described above. Forty-eight hours after dosing, cells were ﬁxed with
100% methanol at−20 °C for 15 min followed by several PBS washes.
The cellswere then treated at room temperaturewith 3% hydrogen per-
oxide, blocked in 5% normal goat serum and avidin/biotin, then incubat-
ed overnight at 4 °C with rabbit polyclonal anti-SCN1A antibody
(Alomone Labs, Israel, cat# ASC-001, validation information at http://
www.alomone.com/p/anti-nav1.1/asc-001/44, accessed 01.16.15) di-
luted 1:250, or rabbit polyclonal IgG (Abcam) diluted to 1:250 or
1:500, or rabbit polyclonal anti-actin antibody (Abcam, UK) diluted
1:500. Then the cells were incubated with goat anti-rabbit antibody
(Vectastain Elite ABC kit, Rabbit IgG, Vector Labs, USA) for 1 h followed
by 30 min with reagents A and B from Vectastain Elite ABC kit. The cells
were then incubated with ImmPACT DAB until the development of theName Sequence
RTprimerNAT-1 CCTTACTGTCTTCATGATGGTCA
RTprimerNAT-2 GCATGCAGCTGTTTGGAA
RTprimerNAT-3 GACTTCTTC CACTCGTTCCT
RTprimerNAT-4 GTTACAAAGATTGTGTCTGCAA
RTprimerMRNA-1 CCCGTCCCTATGCCACTTGT
RTprimerMRNA-2 GTCAGACTCTCCCACAGCA
RTprimerMRNA-3 GTCTACTGTGCTTCCCTCTGA
RTprimerMRNA-4 GTACTTCTCCACACTGCTGCC
Calibration Standard
D00WT
TGATCTAAACAACAAGAAAGACAGTTGTATGTCCAATCATACAGCA
ACTGGCAGCAGTGTTGAAAAATACATTATTGATGAAAGTGATTACA
Calibration Standard
D00mu
TGATCTAAACAACAAGAAAGACAGTTGTATGTCCAATCATACAGCA
ACTGGCAGCAGTGTTGAAAAATACATTATTGATTAAAGTGATTACAT
Calibration Standard
D02WT
GGGAAAATCTTTATCAACTGACATTACGTGCTGCTGGGAAAACGTA
GTGGTGGCCATGGCCTACGAGGAACAGAATCAGGCCACCTTGGAAG
Calibration Standard
D02mu
GGGAAAATCTTTATCAACTGACATTACGTGCTGCTGGGAAAACGTA
TGGTGGCCATGGCCTACGAGGAACAGAATCAGGCCACCTTGGAAGAstaining. The staining of the cells was analyzed directly inside the
wells using an inverted Nikon Eclipse TS100 microscope equipped
with a Nikon DS-Ri1 camera coupled to Nikon Digital Sight equipment
and a Dell Latitude D630 laptop. For each condition there were at least
3 biological replicates. The photographs of the stained cells were con-
verted into black-and-white negative images using the NIS-Elements
D 3.0 software. For eachwell, 4 sections of the same sizewere quantiﬁed
using the NIS-Elements D 3.0 software tools. Statistical analysis was
done using Excel software.
2.6. Sequencing of SCN1A NAT
Candidate SCN1ANAT was identiﬁed based on transcriptome data-
base data related to SCN1A locus. Candidate transcripts were encoded
by the chromosome strand opposite to SCN1A and overlapped SCN1A
gene. Empirical conﬁrmation of these ﬁndings was performed to vali-
date the regulatory effects of these transcripts on SCN1A expression.
The bacterial clone from which the database sequence was obtained
was purchased from Open Biosystems (http://www.openbiosystems.
com/; clone ID 4829512). Ten colonies were picked and grown in 5 ml
of LB broth containing ampicillin at 100 μg/ml. The plasmidwas extract-
ed using PureYield™ Plasmid Miniprep System (Promega, USA) follow-
ing the manufacturer's protocol and bidirectionally sequenced at Davis
Sequencing (USA) using T3 and T7 primers.
2.7. RACE
Total RNA was extracted from HepG2 cells or primary Dravet ﬁbro-
blasts using the QIAGEN RNeasy Midi Kit (QIAGEN, USA) as described
by the manufacturer. PolyA RNA was isolated with the Poly(A)Purist™
MAG Kit and eluted twice with 200 μl of THE RNA Storage Solution
(Ambion, USA).
2.7.1. 3′ End RACE
One μg of total RNA or total RNA polyadenylated using Ambion®
Poly(A) Polymerase (Ambion, USA) or 50 ng of polyA RNA was
reverse transcribed using FirstChoice® RLM RACE Kit (Ambion,
USA). One μl of the RT reaction was PCR ampliﬁed using 5′
GATTCTCCTACAGCAATTGGTA 3′ as the speciﬁc oligonucleotide. Using
1 μl of the ﬁrst PCR reaction, a second PCR was done using 5′
GACATGTAATCACTTTCATCAA 3′ as speciﬁc oligonucleotide following
the FirstChoice® RLM RACE Kit protocol.
2.7.2. 5′ End RACE
Ten microgram of total RNA or total RNA polyadenylated using
Poly(A) Polymerase (Ambion, USA) or 250 ng of polyA RNA were treat-
ed with calf intestine alkaline phosphatase from the FirstChoice® RLM
RACE Kit (Ambion, USA), followed by phenol/chloroform RNAGAAATTGGGAAAGATCTTGACTATCTTAAAGATGTAAATGGAACTACAAGTGGTATAGGA
TGTCATTCATAAACAACCCCAGTCTTACTGTGACTGTACCAATTG
GAAATTGGGAAAGATCTTGACTATCTTAAAGATGTAAATGGAACTACAAGTGGTATAGGA
GTCATTCATAAACAACCCCAGTCTTACTGTGACTGTACCAATTG
CATGATATTTTTTGTATTGGTCATTTTCTTGGGCTCATTCTACCTAATAAATTTGATCCTGGCT
AAGCAGAACAGAAAGAGGCCGAA
CATGATATTTTTGTATTGGTCATTTTCTTGGGCTCATTCTACCTAATAAATTTGATCCTGGCTG
AGCAGAACAGAAAGAGGCCGAA
262 J. Hsiao et al. / EBioMedicine 9 (2016) 257–277extraction, isopropanol precipitation and treatment with tobacco
acid pyrophosphatase to remove any CAP structures. At this time,
an oligonucleotide adapter was covalently linked to the 5′ end
of the RNA. Using 2 μl of the linked RNA, a reverse transcription
using FirstChoice® RLM RACE Kit (Ambion, USA) was performed
at 42 °C for 1 h. One μl of the RT reaction was PCR ampliﬁed using
5′ GTGGAACCTGAAGAAACTCTTG 3′ as speciﬁc oligonucleotide. Using
1 μl of the ﬁrst PCR reaction, a second PCR was done using
5′ GTCCACTCTGGCAGTGCTTGAG 3′ as speciﬁc oligonucleotide follow-
ing the FirstChoice® RLM RACE Kit protocol.
2.7.3. cDNA Cloning
Onemicroliter of secondPCR reaction from the 3′ end or 5′ endRACE
was ligated into a T easy vector (Promega, USA). One microliter of the
ligation reaction was added to OneShot Top10 competent cells
(Invitrogen, USA) using heat shock procedure. One hundred clones
were picked and grown in 5 ml of LB broth containing ampicillin at
100 μg/ml. The plasmid was extracted using PureYield™ Plasmid
Miniprep System (Promega, USA) following the manufacturer protocol.
The inserts were bidirectionally sequenced by Davis Sequencing (USA)
using SP6 and T7 primers.
2.8. RNAseq Experiments
SK-N-AS cells were treated with 20 nM of active AntagoNAT CUR-
1916 or control oligonucleotide CUR-1462 (n = 3/group) and RNA
was extracted as described above. Template DNA molecules suitable
for cluster generation were prepared from 500 ng of total RNA per sam-
ple using the TruSeq RNA Sample Preparation Kit v2 (part # RS-122-
2001, Illumina Inc., San Diego, CA) according to the manufacturer's in-
structions. The size distribution of the libraries was estimated by
bioanalysis using the Caliper LabChip GX system (PerkinElmer; Wal-
tham, MA). The mean size for the libraries was approximately 348 ±
3 nucleotides. Libraries were quantiﬁed using the KAPA Library Quanti-
ﬁcation Kit (Part # KK4824, Kapa Biosystems; Boston,MA). The libraries
were pooled at equimolar concentrations and diluted prior to loading
onto the ﬂow cell of the cBot cluster station (Illumina Inc.; San Diego,
CA). The libraries were extended and bridge ampliﬁed to create single
sequence clusters using the HiSeq PE Cluster Kit v4 cBot (Part # PE-
401-4001, Illumina Inc., San Diego, CA). The ﬂow cell carrying ampliﬁed
clusters was loaded on the HiSeq 2500 sequencing system (Illumina
Inc., San Diego, CA) and sequenced using the 50-nt paired-end plus
index read sequencing protocol with reagents from the HiSeq SBS Kit
v4 (Part # FC-401-4002, Illumina Inc.; San Diego, CA), sequencing
primers from the HiSeq PE Cluster Kit v4, and an index read primer
from the TruSeq Dual Indexing Sequencing Primer Kit (PE-121-1003).
Real time image analysis and base calling were performed using the
HiSeq Control Software version 2.2.58. CASAVA software version 1.83
was used to produce de-multiplexed FASTQ sequence ﬁles from raw
.bcl ﬁles. Sequences were aligned to the human genome version hg19
(UC Santa Cruz) using TopHat v1.4.1. EasyRNASeq v1.6.0 running on
the R version 3.0 platform was used for determination of raw reads
and reads per kilobase per million reads (RPKM) for each gene and
exon. Using a custom R script, further annotation information was
added from Ensembl human version 72 table downloaded from
Ensembl Biomart. Fold changes were calculated and statistical analysis
was performed using R version 3.0 statistical software. False discovery
rates (FDR) were calculated using the method of Benjamini and
Hochberg. If the mean of both groups considered in a fold-change com-
parison were below the Reliable Detection Threshold (50 reads/gene),
“NA” was reported. Differentially expressed genes were deﬁned as
genes with a more than 2-fold difference in expression with p b 0.05
and FDR b 0.05. Functional annotation of genes was performed using
PubMed (http://www.ncbi.nlm.nih.gov/pubmed/, accessed April 15,
2015), Reactome (http://www.reactome.org/, accessed April 15,
2015), StarNet (http://vanburenlab.medicine.tamhsc.edu/starnet2.shtml, accessed April 15, 2015) and neuronal/glial expression databases
(Cahoy et al., 2008).
2.9. Generation of Mouse Model of Dravet Syndrome
The knock-in (KI) mouse strain Scn1aE1099X was generated
in the laboratory of Dr. S.W. Lin (National Taiwan University)
(Tsai et al., 2015). Brieﬂy, a targeting vector was constructed using
recombineering-based method (Liu et al., 2003). Initially, a 15 kb
mouse genomic DNA encompassing exons 10–17 of the Scn1a gene
was isolated from a 129/Sv DNA BAC clone (bMQ419a06, purchased
from Source BioScience, Nottingham, UK) and subcloned into the NotI
and SpeI sites of pL253. A 600-bp fragment containing exon 17 and its
upstreamand downstream sequencewas subcloned into pL452 harbor-
ing a neomycin-resistance cassette surrounded by 2 loxP sites (Cre-
recombinase recognition sequences for removal of the neo cassette).
The nucleotide sequence, GAG, encoding glutamic acid at position
1099 in exon 17 was mutated to TAG (stop codon) by 4-primer PCR
method. The resultant plasmid, pL452-E1099X, was used to insert the
E1099X and the neo-2-loxP cassette into pL253. The resultant targeting
vector, pL253-E1099X, allowed KI of the E1099Xmutation and the neo-
2-loxP cassette into the chromosome of the mouse embryonic stem
cells. The pL253-E1099X targeting vector was linearized with NotI and
electroporated into the R1 hybrid embryonic stem (ES) cells. The ES
cell clones that survived G418 (240 mg/ml) and ganciclovir (2 μM) se-
lectionswere further analyzed by Southern blotting for correct homolo-
gous recombination. Wild type (WT) and KI ES cell genomic DNA
digested by BamHI restriction enzyme generate a 16.5-kb and a 15-kb
fragment, respectively, when detected by a 3′ probe, and a 18.9-kb
and a 12-kb fragment, respectively, when digested by AvaI and detected
by a 5′ probe. To excise the neo cassette from the correctly targeted ES
cell clones, the ES cell clones were electroporatedwith a Cre-expressing
plasmid (pCX-PTD-Cre, constructed in house) that mediates excision of
the loxP-ﬂoxed neo sequences. After transfection, surviving individual
ES cell clones were isolated and their DNA screened by PCR using oligo-
nucleotide primers Scn1a-20,571 U (5′-AGGGAGATGAATGCCAAAGC-
3′) and Scn1a-20,930-2D (5′-GACAATTGGTAGGGAGCACT-3′) in a PCR
reaction with the following conditions: 95 °C for 2 min, followed by
40 cycles of 95 °C for 30 s, 55 °C for 1 min and 72 °C for 1 min, and a
ﬁnal extension at 72 °C for 7 min.WT and the KI allele yielded a respec-
tive PCR products of 359 bp and 459 bp. The resultant KI ES cell clones
were injected into C57BL/6JNarl blastocysts to establish chimeric mice
for germ-line transmission of the Scn1aE1099X/+ allele through breeding
processes. Conﬁrmation of germline transmission was performed by
genotyping, sequencing, and Southern blotting of the genomic DNA of
the ﬁrst offspring of chimeric mice. Genotypes of subsequent genera-
tions were analyzed by PCR as described above. Mating of chimeras
was conducted as follows. Generation I: offspring of chimeric mice [de-
rived from RI (129 × 1 × 129S1) ES cells] mated with 129 female mice
(129S2/SvPasCrl; Charles River). Generation II (N1F1): male offspring
of generation I mated with C57BL/6JNarl (purchased from National An-
imal research Laboratory, Taiwan) female mice. Generation III (N2F1):
male offspring of generation II mated with C57BL/6JNarl female mice.
Animals were genotyped for the presence of the KI allele (Scn1aE1099X)
and uniquely identiﬁed by toe clipping displaying the animal number.
2.10. AntagoNAT Treatment and EEG Recording in Dravet Mice
Seven week old naïve Dravet mice were housed individually for du-
ration of experiment. Food (5001 rodent diet, LabDiet) and water were
offered ad libitum. Light/dark (12 h/12 h) cycle was maintained. Ani-
mals were assigned to different groups using the stratiﬁed randomiza-
tion procedure based on gender, animal weight and age. All animal
procedures were approved and controlled by the Taiwan National Uni-
versity ethics committee and carried out according to the institutional
animal care and use guidelines. All experiments were planned and
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reporting (Landis et al., 2012).
2.10.1. EEG Electrode Implantation
Mice were anesthetized by intraperitoneal injection of Zoletil
(4.13 mg/kg) and surgically implanted with two electroencephalogram
(EEG) wire electrodes. Insulated leads from EEG electrodes were routed
to a pedestal. The pedestal was then cemented to the skull with dental
acrylic (Tempron, GC Co., Tokyo, Japan). The incision was treated topi-
cally with polysporin (polymixin B sulfate/bacitracin zinc) and the ani-
mals were allowed to recover for 6 days prior to the initiation of
experiments. Ibuprofen (15 mg/100 ml) was added into the drinking
water for two days after surgery. Four days after surgery, a tether was
connected to the EEG electrodes.
2.10.2. EEG and Video Monitoring
EEG and video monitoring in these studies was conducted continu-
ously 24h a day every day for thewhole period of AntagoNAT treatment
(28–30 days) until animal sacriﬁce. EEG recordingswere analyzed using
Axoscope software by visually identifying the times of increased activity
followed by a depression, and recording time of onset, duration and am-
plitude of each seizure episode. All instances of seizures identiﬁed by
analysis of EEG traces were veriﬁed using video recordings. Seizure se-
verity was graded based on EEG and video data according to the follow-
ing scale: stage 3— tremor in the front feet and back, rigidity in the tail,
seizure amplitude on EEG 2 mV–3.5 mV; stage 4 — tremor in front and
back legs and back, rigidity in the tail, mice are unable to maintain their
standing posture and fall down, seizure amplitude 3.6 mV–4.5 mV;
stage 5 — generalized tremors cause sudden jumps, seizure amplitude
on EEG over 4.6 mV. EEG analysis was conducted by 2 independent ob-
servers blinded to the treatment.
2.10.3. Intrathecal Administration of AntagoNATs
AntagoNATs used in mouse studies were CUR-1901 and CUR-1924
(synthesized by IDT Inc.). CUR-1901 was administered once weekly
for 4weeks. Threemicroliters of AntagoNAT solution at desired concen-
tration followed by 2 μl of saline vehicle were injected intrathecally
using the method of Hylden and Wilcox (1980). Brieﬂy, after mice
were lightly anesthetized with ketamine (100 mg/kg) the spinal space
was identiﬁed by inserting a 30-gauge needle at a 20″ angle cephalad
between adjacent lumbar spinal processes (L5–6). Resistance encoun-
tered at a depth of approximately 5 mm indicated proper position of
the needle tip within the spinal canal. AntagoNATswere injected slowly
using a 100-PL syringe (Hamilton Co., Reno, NV). The L5–6 interspace
approximates the termination of the spinal cord and the origins of the
cauda equina. Injection at this site maximizes intervertebral accessibili-
ty and minimizes the likelihood of spinal cord damage. The animals
remained under the inﬂuence of anesthetic for 2–7 h under continuing
EEG and video recording. Correct targeting of the injection was con-
ﬁrmed using a dye solution.
2.11. Heat Induction of Seizures
Mice were placed in the transparent acrylic cylinder approximately
30 cm tall, 9 cm in diameter and 0.3 cm thick. An infrared heating
lamp suspended approximately 10 cm over the top of the cylinder
was used to pre-heat the cylinder for 15 min before experiment start,
ensuring even temperature within the cylinder and in the surrounding
area. The temperature was increased without thermal feedback, in 3
standard, pre-set steps 10/5/5 min long. Core body temperature was
continuously recorded using a rectal probe (TD-300 NATSUME, Japan).
Behavioral seizure start was deﬁned as clonic forelimb cramps, stiffen-
ing of the body and shaking of the tail. At seizure start the lamp was
turned off. Mice were then returned to home cage and closely moni-
tored for several hours. Core body temperature at seizure start wasrecorded as the threshold temperature. Mice were videotaped during
heat induction.
2.12. Electrophysiological Experiments
2.12.1. Brain Slice Preparation
Acute hippocampal slices were prepared from mice of 5–6 weeks
old. Brieﬂy, mice were decapitated, and the brains were quickly re-
moved and immersed in ice-cold oxygenated slicing solution containing
(in mM): 250 sucrose, 2.5 KCl, 0.5 CaCl2, 5 MgCl2, 1.26 NaHPO4, 26
NaHCO3, and 15 glucose aerated to a pH of approximately 7.4 with
95% O2–5% CO2. Coronal brain slices (300 μm) were cut in cutting solu-
tion on a microslicer (DTK-1000, Dosaka, Kyoto, Japan) and transferred
to a holding chamber containing artiﬁcial cerebrospinal ﬂuid (ACSF)
consisting of (in mM): 125 NaCl, 2.5 KCl, 2 CaCl2, 1 MgCl2, 1.26
NaHPO4, 26 NaHCO3, and 15 glucose aerated with 95% O2 and 5%CO2.
The slices were then maintained at room temperature (23 ± 2 °C) for
at least 1 h before recording.
2.12.2. Electrophysiological Eecordings
During recording, slices were placed in a recording chamber and
continuously perfused with ACSF. Recordings were made at room tem-
perature. The resistance of the patch electrodewas 3–8MΩ. Whole-cell
patch-clamp recordings were acquired with an Axopatch 200B ampliﬁ-
er (Molecular Device, Foster City, CA). Nav1.1 is mainly expressed in
parvalbumin (PV)-positive GABAergic interneurons of the brain
(Ogiwara et al., 2007). PV-positive interneurons were recognized by
their large soma (N30 μm) and location at the border of granule layer
in the dentate gyrus and the typical fast-spiking ﬁring patterns. The ﬁr-
ing activity of PV-positive interneurons was recorded under current
clamp using K-gluconate-based internal solution containing (in mM):
140 K-gluconate, 9 NaCl, 1 MgCl2, 1 EDTA, 10 HEPES, 2 Mg-ATP, 0.3
Na-GTP and 10 biocytin, pH adjusted to 7.3 with KOH. After recording,
slices containing biocytin-ﬁlled cells were ﬁxed with 4% paraformalde-
hyde overnight at 4 °C and then reacted with Texas Red-avidin
(1:200; VectorLab, Burlingame, CA) and rabbit anti-PV primary anti-
body (1:500, Millipore). The secondary antibody used was Cy5-conju-
gated anti-rabbit IgG (1:200, Jackson ImmunoResearch Laboratories).
PV-positive recorded neurons displaying typical fast-spiking activity
were collected for further analysis. The input-output function was de-
termined by the action potential (AP) number in response to a series
of depolarizing current pulses of 1 s. Data were acquired using Clampex
10.2 software (Molecular Devices), ﬁltered at 5 kHz, digitized at 10 kHz,
and recorded directly on the computer hard disk using AxoScope 10.2
software (Molecular Devices). Firing activity was analyzed using
Clampﬁt 10.2 (Molecular Devices). Input resistance was calculated
from the voltage difference between steady state and a 1-s long hyper-
polarizing current injection of−50 pA. AP properties were measured
from the ﬁrst AP in the depolarizing protocol. The AP threshold was de-
termined as the ﬁrst point in the voltage trajectory with a slope change
exceeding 20 V/s. The AP amplitude was measured from the threshold
to the peak of the spike. The AP properties were measured from
the ﬁrst AP in the depolarizing protocol. The slopes were calculated
during the 10–90% rise phase and the 90–10% decay phase of the
AP. The AP half-width was measured at half-maximal amplitude.
Afterhyperpolarization (AHP) was measured as the voltage difference
between the threshold and the most negative voltage point in AP.
2.13. AntagoNAT Treatment in African Green Monkeys
The studies in African green monkeys (Cercopithecus aethiops
sabaeus) were conducted by RxGen at the St. Kitts Biomedical Research
Foundation, St. Kitts,West Indies. Animalswere housed in a primate en-
closure. Humidity and temperature of the housing enclosure was mon-
itored for the duration of the study. All animal procedures were
approved and controlled by the St. Kitts Biomedical Research
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tional animal care and use guidelines. All experiments were planned
and carried out according to the NINDS guidelines for transparent data
reporting (Landis et al., 2012). AntagoNATs CUR-1916, CUR-1740,
CUR-1945, CUR-1837 and a control oligonucleotide CUR-1462 were
used in these studies. AntagoNATs were synthesized by Ribotask ApS
(Denmark) and BioSpring Gesellschaft für Biotechnolgoie mbHTable 1
Alignment of human (H), monkey (R) and mouse (M) Scn1aNATs. Nucleotides 721 to 1123 o
4,829,512 and RACE experiments. Context sequence for human/monkey SCN1ANAT gene e
underlined. Nucleotides 8–170 are derived from an LTR12E repeat (family ERV1).(Germany). Adult naïve male animals were allocated to groups by
means of a stratiﬁed randomization procedure based on body weight.
A single percutaneous CSF tap/infusion was conducted under keta-
mine/xylazine sedation [5.0 mg/kg ketamine (Fort Dodge)/1.0 mg/kg
xylazine (Lloyd Lab) administered intramuscularly in a sterilely mixed
cocktail]. Prior to CSF infusion monkeys were placed in a prone position
with one study participant stabilizing the head in ﬂexion. The test orf human SCN1ANAT (shown in italics) were revealed by additional sequencing of clone
xpression assay is highlighted in bold, sequences complementary to AntagoNATs are
265J. Hsiao et al. / EBioMedicine 9 (2016) 257–277control article was loaded into a syringe coupled to a three-way stop-
cock, the male port on which was attached to a 22 gauge 1.5 in. needle
and the female port to another empty 1 cm3 polycarbonate Luer-lock sy-
ringe to apply negative pressure for controlled withdrawal of CSF to
conﬁrm entry into the CSF space. A second study participant thenpercutaneously introduced the needle into the cisterna magna by
atraumatically gliding the needle tip down the poster aspect of the oc-
cipital bone to the foramen magnum. Two hundred and ﬁfty milliliters
of CSFwas then slowlywithdrawn over a 10–30 s interval, and the stop-
cock turned to allow delivery of the test or control article, with
Fig. 2. Summary of AntagoNAT screening data. Bars show fold difference in the SCN1A mRNA expression levels between mock-transfected controls and cells treated with 20 nM of
AntagoNATs of different chemistry and sequence. Boxes point to AntagoNATs selected for in-depth studies based on their high SCN1A upregulation and effect consistency in different
cell lines. For mouse, homology to human AntagoNATs was also taken into account. Each bar represents an average of 2 or more experiments in 2 different cell lines (HepG2 and SK-
N-AS cells for human, 3T3 and Neuro2a cells for mouse-speciﬁc AntagoNATs, n= 10 or higher). Real time PCR data. Mean ± S.E.M. * — p b 0.05.
266 J. Hsiao et al. / EBioMedicine 9 (2016) 257–277reintroduction of sufﬁcient CSF to ﬂush the test and control article from
the catheter dead space. After successful needle withdrawal, the mon-
key was transferred to home cage. General animal well-being was
assessed before, during and after sedation and anesthesia. A behavioral
summary scorewas applied to evaluate treatment associated behavioral
changes based on an objective, inter-rater reliable, quantitative rating of
behavior by a well established protocol (Taylor et al., 1997). Behavior
was observed twice at approximately the same time of day for a 5 min
period prior to and after test article delivery. The total behavioral sum-
mary score (BSS) was derived from the summed activity measures at
each observation time point, incorporating cumulative incidence per
5 second interval over the 5 minute observation period of the following
healthy normal behaviors: shift, tail ﬂag, yawn, chew, scratch, vocaliza-
tion, self groom, cage pick, eating, drinking, threaten, lookout, lick ﬁn-
gers, cage lick, and vertical climb. Seven days after test or control
article dosing the monkeys were euthanized with intravenous sodium
pentobarbital followed by transcardial perfusionwith chilled 0.9% saline
for approximately 10 min to minimize residual intravascular blood and
allow optimal sectioning of the brain. At the time of sacriﬁce animals
were examined carefully for external abnormalities including hair loss,
palpable masses, and abnormalities in the abdominal and thoracic cav-
ities. Brain, spinal cord, heart, lung, liver, spleen, and kidney specimens
were dissected and punch biopsies obtained and ﬂash frozen forTable 2
SCN1ANAT sequence conservation.a
Score Length Identity, %
Chimpanzee 1097 1115 99.3
Orangutan 1058 1116 97.7
Gorilla 1035 1058 99.2
Rhesus 886 952 97.7
Marmoset 855 952 95.0
Pig 541 752 91.4
Mouse 371 475 89.1
Chicken 290 444 82.1
Zebraﬁsh 40 280 97.7
C. elegans 20 25 88.5
a Identity to human. Columns LENGTHand IDENTITY refer to the regions of highhomology onl
is 1123 nucleotides.bioanalytical and pharmacodynamic analyses. The remaining harvested
CNS tissue was post-ﬁxed in 4% paraformaldehyde, then transferred to
PBS with 0.05% azide and retained for histological analysis. Brain tissue
processing and histopathological analysis was conducted by HistoTox
Labs Inc. (Boulder, CO).
2.14. AntagoNAT Detection In Situ
Formalin ﬁxed monkey brain specimens were parafﬁn-embedded
and sectioned into 8 μm slices that were then adhered onto charged
glass slides. To perform Fluorescent In Situ Hybridization (FISH), the
slides were heated at 70 °C for 30 min, deparafﬁnized by passing
through a xylene and ethanol series, microwaved in 10 mM citrate
buffer for antigen retrieval andwashed in PBS. The tissue slideswere in-
cubated in a pre-hybridization buffer (3% BSA in saline-sodium citrate
(SSC)) at 65 °C followed by treatment with the AntagoNAT-speciﬁc
LNA probe labeled with TYE™ 563 (TYE™ 563/+G+GG+TG+AT+-
CTG+AA+TT+TGT+GAC+TG, where + designates an LNA modiﬁ-
cation) denatured for 5 min at 75 °C and dissolved in hybridization
buffer (10% Dextran Sulfate in SSC), for 1 h at 65 °C. After probe anneal-
ing, the slides were extensively washed in wash buffers (SSC and PBS).
The slides were blocked in donkey serum then incubated with primary
antibody for parvalbumin (R&D Systems, USA) overnight at 4 °C,Chromosome Locus Start End
2B Scn1a 8 1123
2b Scn1a 7 1123
2B Scn1a 65 1123
12 Scn1a 171 1123
6 Scn1a 171 1123
15 Scn1a 339 1091
2 Scn1a 400 875
7 Scn1a 405 849
11 n/a 523 803
I n/a 786 811
y. Columns START and END showpositions on SCN1ANAT. Total length of human SCN1ANAT
Fig. 3. SCN1Aand SCN1ANATexpression inhuman,monkey andmouse tissues. (a) Expression of SCN1ANAT ina human tissue panel, normalized to arbitraryRNA standard. (b) Correlation
of expression levels of Scn1a and Scn1aNAT in African greenmonkey tissues (n=4, df= 20, F= 29.5; tissues as listed in (e), dark circles— peripheral organs, lighter circles— spinal cord,
light circles— brain regions). (c) Ratio of Scn1a to Scn1aNAT expression inmouse tissues, n=4. (d) Ratio of Scn1a to Scn1aNAT expression inmouse cell lines. (e–g) Expression levels of
Scn1a and Scn1aNAT in African greenmonkey tissues, n=4: (e)— Scn1amRNA. (f)— Scn1aNATRNA. (g)—Ratios of Scn1a to Scn1aNAT copynumbers. (h–j)— Enlarged portions of e, f, g
respectively showing data for peripheral organs. Real time PCR data. Mean ± S.E.M.
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488 (Jackson ImmunoResearch, USA) diluted 1:250 in PBS for 1 h at 37 °
C. Lastly, the slides were washed again with PBS and cover slipped in
Vectashield mounting media with DAPI (Vector Laboratories).
2.15. Hybridization Assay
A hybridization assaywas developed to determine concentrations of
the AntagoNAT CUR-1916 in biological samples from animal studies in-
cluding plasma, CSF, brain and peripheral organ tissues. Brieﬂy, we de-
signed 2 probes to speciﬁcally detect CUR-1916: a capture probe
(5AmMC12//iSp18//iSp18/
G*G*G*+T*+G*+A*+T*+C*+T*+G*+A*+A*+T where * designates
a phosphorothioate bond, + designates LNA modiﬁcation, 5AmMC12is 5′-aminomodiﬁer C12m, Sp18 is an internal 18-mer spacer) and a de-
tection probe (+T*+G*+A*+C*+T*+G*+G*+C*+T*+C/iSp18//
iSp18//iBiodT//3BioTEG, where iBiodT is an internal biotin-dT, 3BioTEG
is a 3′ biotin-TEG, all manufactured by IDT Inc.). DNA-Bind plates were
incubated with capture probes overnight, then blocked with bovine
serum albumin for 2 h. Biological samples were mixed with detection
probes in a sample preparation plate and heated at 90 °C for 12.5 min.
The detection probes/sample mixtures were then transferred to the
capture plate and incubate at 45 °C for 2 h. The plate was incubated
with Streptavidin HRP for 30 min followed by TMB substrate for
30 min in the dark. The reaction was stopped with sulfuric acid. Absor-
bance was measured using a spectrophotometer at 450 nm with back-
ground correction set to 650 nm. The hybridization method was
validated using known amounts of AntagoNAT added to brain tissue
Fig. 4. Target speciﬁcity of NAT-mediated SCN1A upregulation. (a) SCN1AmRNA in SK-N-AS cells treated with a mixture of active AntagoNAT (CUR-1837) and a control oligonucleotide
(CUR-1462); ANOVA p b 0.01,n=3–5. (b)Vero76 cells treatedwith amixture of an active AntagoNAT (CUR-1916) and control oligonucleotide (CUR-1462); ANOVA p b 0.05,n=5/group,
representative of 4 experiments. (c) SCN1AmRNA levels in SK-N-AS cells treated with 20 nM of an active AntagoNAT (CUR-1916) or inactive oligonucleotides of different sequence and
chemistry (except CUR-1462_40 at 40 nM; ANOVA p b 0.001, n= 6/group, representative of 11 experiments). Real time PCR data. Mean ± S.E.M., * — p b 0.05, **— p b 0.01, ***— p b 0.001.
268 J. Hsiao et al. / EBioMedicine 9 (2016) 257–277extracts from untreated monkeys. Validation of the method included
speciﬁcity/dilution linearity, working calibration range, lower limit of
quantitation and intra-assay precision and accuracy. The lower limit of
quantitation was determined to be 0.4 ng/ml, and the back-calculated
concentrations of the calibration standards were within ±20% of their
theoretical concentrations over the working range of 0.4 to 10 ng/ml
using a 4-parameter logistic curve ﬁt (SoftMax PRO, Version 5.4.1, Mo-
lecular Devices Corporation). Intra-assay accuracy was within ±20%
of the nominal concentrations (±25% for the lower limit of quantita-
tion) and precision was within 20%. Samples of monkey brain lysate
containing AntagoNATwere shown to be stable in at room temperature
for over 4 h and after four freeze-thaw cycles at approximately−20 °C.
Themolar concentration of AntagoNAT in the tissue can be calculated byFig. 5. Treatment with AntagoNATs did not affect expression of highly homologous alpha subu
(n=5, p b 0.001 for Scn1a). (b, c) Dravet patient ﬁbroblasts D-00 treated with different concen
p N 0.05 for other genes, n=5/group. (d, e) mouse 3T3 cells (n=10/group, p b 0.02 for Scn1a)
vivo (n= 9, p b 0.01 for Scn1a, t-test with Bonferroni correction, p N 0.3 for all other genes). (h
(ELISA, n = 3, 1-factor ANOVA p N 0.05 for actin, p b 0.05 for Scn1a). (j) IHC staining for Nav
(k) magniﬁcation of (j), 1 — no primary antibody, 2–0 nM, 3.4–40 nM of CUR-1901 or CUR-
upregulates Nav1.1 (l, m, p) but not actin (n, o) protein levels (IHC staining, NIS-ElementsD3.
* — p b 0.05, **— p b 0.01, *** — p b 0.001.dividing the detected amount of AntagoNAT by its molar mass
(8566.9 g/mol). For example, AntagoNAT concentrations in the CSF
seven days after injection were 5.27 ± 1.99 ng/ml (or 0.615 nM) at
the 0.008 mg/kg dose and 16.79 ± 4.12 ng/ml (or 1.96 nM) at
0.04 mg/kg (n= 6).
2.16. Statistical Analysis
Data was analyzed using Excel except where noted. t-Tests were
used when 2 groups were compared, one-factor ANOVAs when com-
paring a single factor in N2 groups, two-factor ANOVAs were used to
comparemore than one factor in N2 groups, (both ANOVAswith custom
Tukey post-hoc test), t-testwith Bonferroni correctionwas usedwhen 2nits of sodium channels and unrelated genes. (a) Human SK-N-AS cells, 20 nM CUR-1916
trations of (b) CUR-1770 or (c) CUR-1916; real time PCR data, ANOVA, p b 0.05 for SCN1A,
, (f) monkey temporal cortex in vivo (n=9, p b 0.01 for Scn1a), (g) Dravet mouse brain in
, i) Protein levels in Vero76 cells after treatment with CUR-1916: (h) Nav1.1 and (i) actin
1.1 after treatment of Neuro2a cells with CUR-1901 (top panel and CUR-1924 (bottom),
1924 respectively. (l–p) — Treatment of Dravet ﬁbroblasts with 80 nM of AntagoNATs
0 software, n= 4, 2-factor ANOVA p b 0.05 for actin, p b 0.05 for Scn1a). Mean ± S.E.M.,
Fig. 6. Secondary structure of SCN1ANAT. Blue triangles— low-activity, red triangles—high-activity AntagoNAT clusters. AntagoNATs inducinghighest upregulation of SCN1Awere located
around positions 540 and 1018 (representative AntagoNATs CUR-1740 and CUR-1916 respectively). Color scale represents probability of occurrence of the secondary structure (blue —
low, red — high). Generated using Vienna RNAfold software.
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conﬁrm an increase/decrease trend in one factor depending on another,
andmultiple regressionwas used to estimate the degree and probability
of determination of one factor bymultiple other factors. Excel F-test tool
and QQplots, respectively, were used to compare sample variances and
estimate normality. Fisher exact test was used to compare frequencies
by an on-line calculator (Preacher and Briggs, 2001). Statistical analysis
of RNAseq results is described in corresponding section. Group size de-
termination was conducted using custom calculator. Sample size in all
studies was calculated assuming alpha of 0.05 and power of 0.80 using
standard deviation values estimated in pilot experiments. All tests
were 2-sided. Criteria for data exclusionwere deﬁned for each analytical
technique in lab SOPs at the time ofmethod validation experiments. Sci-
entists carrying out animal treatment and analytical tests were blinded
to group assignments. Analytical tests, animal treatment and data anal-
ysiswere carried out by independent groups of scientists. All data is pre-
sented as mean± S.E.M., group size is indicated in ﬁgure legends or on
the graphs.
3. Results
3.1. SCN1A Locus is Regulated by NATs in Different Species
In the NCBI transcript database we identiﬁed an RNA transcript
expressed from the opposite DNA strand of the human SCN1A locus
that we named SCN1ANAT (accession number BG724147, Fig. 1a). We
then sequenced the complete insert of the BG724147 cDNA clone, ex-
tending SCN1ANAT to 1123 nucleotides. Seven additional sequences inFig. 7. Mouse model of Dravet syndrome. (a) Localization of the E1099Xmutation in the Scn1a
real time PCR data, n = 3. (c) Example of a 12-hour long EEG recording showing typical seizu
arrows); representative of the 28-day continuous observation of N30 mice (video in Supplemethe NCBI database closely homologous to BG724147 have been cloned
from several tissues by different authors. To better deﬁne the bound-
aries of SCN1ANAT we performed 3′and 5′-RACE experiments using
RNA from Dravet ﬁbroblasts, testes and HepG2 cells, which conﬁrmed
the 3′-end of SCN1ANAT (Table 1).
To study the potential regulatory effects of this ncRNA on SCN1A ex-
pression, we designed N70 oligonucleotide-based compounds, termed
AntagoNATs, targeting different regions of SCN1ANAT, and transfected
them in several cell lines. In these experiments 86% of the AntagoNATs
induced an increase in SCN1AmRNA levels at the initial screening con-
centration of 20 nM, suggesting that SCN1ANAT acts as a negative regu-
lator of SCN1A expression (Fig. 2).
The Scn1aNAT sequences are highly conserved in primates, but have
only limited homology in pig, mouse and chicken (Table 2). Notably, in
these species small regions of homology to SCN1ANATmap to the Scn1a
loci, supporting functional conservation. Examination of mouse data-
bases yielded two potential Scn1aNAT sequences. We focused on the
Scn1aNAT1 (Fig. 1b) because its position relative to the Scn1a coding re-
gions was similar to human SCN1ANAT. We then designed 36 mouse-
speciﬁc AntagoNATs and showed that N80% of them induced Scn1a up-
regulation in 4 mouse cell lines, thus conﬁrming the conserved regula-
tory activity of Scn1aNAT1 in repressing Scn1a expression (Fig. 2).
3.2. SCN1ANAT is Expressed in Multiple Tissues
SCN1A is normally expressed in multiple excitable and non-excit-
able cells, reﬂecting its roles in generating action potentials andmainte-
nance of cellular homeostasis (GNF Expression Atlas 2; The Humanprotein structure. (b) Scn1a mRNA expression in Scn1a E1099X/+mice compared toWT,
re (square bracket), post-seizure depression (slim arrow) and inter-ictal activity (block
ntary File 3). Mean ± S.E.M.
Fig. 8. SCN1A upregulation and seizure phenotype improvement in a mouse model of Dravet syndrome after AntagoNAT treatment in vivo. Mice were treatedwith 4 weekly injections of
CUR-1901 at 20 μg/injection or saline. (a, b) Dose-dependent increase in Scn1a mRNA levels in brain regions of Scn1a E1099X/+ (a) or WT (b) mice (real time PCR data, normalized to
vehicle control, ANOVA p b 0.05 for each brain region, stars show comparison to 0 μg). (c) Average number of seizures recorded during the 12 h light (LIGHT) or dark (DARK) periods,
and TOTAL throughout the day (average over 28 days; n = 10 for CUR-1901, n = 11 for control, t-test with Bonferroni correction). (d) Total number of seizures from (a), symbols
represent averages for individual animals. (e) Dose-dependent reduction in daily seizure numbers (regression p= 0.01). (g–i) Reduction in (g) seizure duration, (h) ictal amplitude
and (i) post-ictal amplitude (n= 6 for CUR-1901, n= 5 for saline, t-test with Bonferroni correction). Mean ± S.E.M. * — p b 0.05, **— p b 0.01.
270 J. Hsiao et al. / EBioMedicine 9 (2016) 257–277Protein Atlas). However, SCN1A expression in non-neuronal tissues and
cultured cells is 10–1000 times lower than in the CNS. Correspondingly,
SCN1ANAT expression was also observed in all human, monkey and
mouse tissues tested, with highest levels in the brain and testes (Fig.
3a, f, i). In order to estimate the average level of SCN1ANAT
(AC010127.3) in cells we analyzed data from the Developmental Tran-
scriptomeproject of the BrainSpanAtlas. This project consists of RNAseq
data proﬁling up to 16 cortical and subcortical regions across 13 devel-
opmental stages. One copy of a transcript per cell corresponds to reads
per kilo base per million mapped reads (RPKM) values between 0.5
and 5, depending on the total amount of RNA per cell (Mortazavi et
al., 2008). In the BrainSpan data the average RPKM value for SCN1ANAT
is 1.28, corresponding to approximately one transcript of SCN1ANAT
per cell. The SCN1A/SCN1ANAT ratio in a pooled sample of 3 human
brains was comparable to the average African green monkey brain
ratio (64.7 ± 8.5 and 138 ± 58, respectively), while the ratio in the
mouse CNSwas signiﬁcantly lower (2.6±0.7, Fig. 3). Scn1aNAT expres-
sion positively correlatedwith Scn1amRNAexpression inmostmonkey
tissues (r2 = 0.61, p b 0.001; Fig. 3b). The positive correlation between
SCN1A and SCN1ANAT expression could reﬂect the need for a larger
pool of replacement NAT molecules in more active loci due to higher
probability of NAT molecule damage or displacement.3.3. Effects of Blocking SCN1ANAT are Highly Gene-speciﬁc
We then investigated if the increase in transcription induced by
blocking SCN1ANAT is speciﬁc to the SCN1A gene. In the ﬁrst set of ex-
periments, an inactive control oligonucleotide with no homology in
the human genomewas added to an active AntagoNAT of similar chem-
istry to keep the combined oligonucleotide concentration constant. After
treatment of SK-N-AS cells with this oligonucleotide mix, SCN1AmRNA
levels increased proportionally to the dose of the active AntagoNATs, but
not the control oligonucleotide or total chemistry load (Fig. 4a). We re-
peated this experiment using different AntagoNATs and cell lines and
observed that SCN1A upregulation was not associated with a particular
AntagoNAT sequence, chemistry or cell line (Fig. 4b), indicating that the
effect was target-dependent. Similar effect was observed at the protein
level (Fig. 5j–p). SCN1A levels in cells treated with inactive oligonucleo-
tides did not differ from mock-transfected controls (Fig. 4c).
In the second set of experiments we showed that treatment with
AntagoNATs targeted against SCN1ANAT did not affect the expression
of other alpha subunits of sodium channels, which are highly homolo-
gous to SCN1A (SCN2A, SCN3A, SCN9A, SCN7A, SCN8A) and of unrelated
genes, localized either next to SCN1Aon chromosome 2 (Ttc21b) or on a
different chromosome (actin). The absence of effect was observed in
human andmouse cell lines (Fig. 5a-e) and in vivo in African greenmon-
keys andDravetmice (Fig. 5f–g). Expression of the studied genes in cells
treated with inactive oligonucleotides was not different from mock-
transfection or vehicle controls.
In the third set of experiments we performed high throughput RNA
sequencing (RNAseq) to compare the transcriptomes of SK-N-AS cellstreatedwith either an active AntagoNAT (CUR-1916) or an inactive con-
trol oligonucleotide of similar chemistry (CUR-1462). Sequencing gen-
erated a minimum of 76,000,000 passed-ﬁlter-paired-end reads per
sample, which aligned to the reference genome at an average 83% ±
0.5% efﬁciency and mapped to N31.000 genes (Supplementary File 1).
Differential expression analysis showed that 90.3% of the expressed
genes did not differ between cells treated with the active and control
AntagoNATs. Similarly to what we observed using real time PCR,
RNAseq results showed that SCN1A levels in the active AntagoNAT-
treated samples were upregulated 4.2 fold compared to control
(p b 0.0001, FDR = 0.00001). Expression of other sodium channel
genes (SCN2A, SCN3A, SCN5A SCN7A, SCN8A, SCN9A, SCN1B, SCN3B),
as well as genes ﬂanking SCN1A on chromosome 2 (TTC21B and
SCN9A) did not differ between the two groups (Supplementary File
1). Of the 9.7% of genes with signiﬁcant changes in expression, 56% rep-
resented non-coding RNA (pseudogenes, lincRNA, miRNA, NATs, rRNA,
snRNA, and other types) with little or no information on their function.
The remaining 44% were protein-coding genes. Among protein coding
genes, 28% had no known function (Supplementary File 2). Based on
the information about the remaining 72% of the differentially expressed
protein-coding genes obtained from different annotation tools, they
could be divided into 2 major groups: 1) housekeeping genes needed
to support increased RNA and protein expression (57%), and 2) genes
involved in neuronal and astrocytic differentiation (43%, Supplementary
File 2). The increased expression of these genes could occur as a down-
streameffect of theAntagoNAT-mediated increase of SCN1A expression.
SK-N-AS is a human neuroblastoma cell line, which represents a mixed
population of cells resembling early neuronal and glial phenotypes
(Thiele, 1998). SK-N-AS cells are known to differentiate spontaneously
or under external stimuli, including overexpression of certain genes
(e.g. TRKB, RET), giving rise to a mix of neuronal- and glial-like cells
(Thiele, 1998). Interestingly, in active AntagoNAT-treated samples ex-
pression of anticonvulsant neuropeptides and their receptors, including
neuropeptide FF (NPFF), neuropeptide FF receptor 2 (NPFFR2), galanin
receptor 2 (GALR2) and ghrelin/obestatin prepropeptide (GHRL), was
upregulated or likely upregulated compared to controls (Supplementa-
ry File 1).
Taken together, the results from the 3 sets of experiments indicate
that SCN1ANAT-mediated increase of SCN1A expression does not result
from spurious qualities of one AntagoNAT, non-speciﬁc chemistry ef-
fect, generalized transcriptional upregulation or class effect involving
all sodium channels. In addition, it is restricted to genomic SCN1A
locus, while the expression of highly homologous and adjacent genes,
and of N90% of all expressed genes, remains unchanged.3.4. Secondary Structure of SCN1ANAT Determines the Degree of
AntagoNAT Effect
While 86% of AntagoNATs designed against SCN1ANAT induced
SCN1A upregulation at 20 nM, the scale of upregulation was different
(Fig. 2). One possible reason for these differences is the localization of
Table 3
Multiple regression of seizure numbers on Scn1a levels in different brain regions of Scn1aE1099X/+ mice.a
Regression statistics
Multiple R 0.815
R squared 0.664
Adjusted R squared 0.472
Standard error 0.487
Observations 23
ANOVA
df SS MS F Signiﬁcance F
Regression 8 6.546871646 0.818 3.455711 0.020648545
Residual 14 3.315388717 0.237
Total 22 9.862260363
Coefﬁcients Standard error t stat p-Value
Intercept −2.71 1.516 −1.79 0.0951
Cerebellum 1.09 1.006 1.085 0.2962
Hypothalamus 0.70 0.772 0.905 0.3807
Hippocampus 2.55 0.968 2.633 0.0197
Striatum −0.14 0.590 −0.233 0.8190
Frontal cortex 1.08 0.978 1.107 0.2869
Occipital cortex −1.12 0.485 −2.316 0.0362
Temporal cortex 0.50 0.569 0.871 0.3983
Parietal cortex −1.12 0.431 −2.603 0.0208
a Scn1aE1099X/+micewere continuously EEG- and video-monitored for a 28-day period starting at postnatalweek7, afterwhich SCN1AmRNA levels in regions covering thewhole brain
were determined by real time PCR. Multiple regression on this data shows that 66% of the variation in seizure frequency could be explained by differences in Scn1a levels (p=0.02; n=
23). Scn1a levels in a subset of brain regions signiﬁcantly correlated with the number of seizures.
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To test this hypothesis, we designed a set of 19- to 21-base AntagoNATs
covering full human SCN1ANAT sequence. When their ability to up-
regulate SCN1A in different cell lines was compared, AntagoNATs
complementary to sequences around positions 540 and 1018 of
SCN1ANAT had the highest activity. In themodel generated using Vienna
RNAfold software (Gruber et al., 2008), these regions folded together into
the same area of the SCN1ANAT secondary structure (Fig. 6). We con-
ﬁrmed these ﬁndings using two algorithms available in RNAfold, as well
as in the Moscow University RNA Secondary Structure Prediction Tool,
with highly similar results. These ‘hotspot’ regions may be essential
for SCN1ANAT folding and function and/or be easily accessible to
AntagoNATs.
3.5. Transgenic Mouse Carrying a Dravet Mutation Closely Mimics Human
Disease
To test whether Scn1a upregulation after birth would lead to an im-
provement of disease symptoms in vivo, we injected AntagoNATs in
transgenic mice harboring a known Dravet mutation E1099X (Fig. 7a),
created in the laboratory of Dr. S.W. Lin (Tsai et al., 2015). Thea b c
Fig. 9. Increase in seizure threshold temperature after CUR-1901 treatment. Scn1a E1099X/+ (
saline. (n=4.6, representative of 3 experiments, t-test p=0.01). (c) Cumulative seizure proba
CUR-1901 or vehicle (n=3.3,6,5 respectively, representative of 3 experiments). (d) Power spec
ictal suppression EEG (black trace) in Scn1aE1099X/+ transgenic mice (n= 6).Mean ± S.E.MScn1aE1099X/+ model closely resembled previously described knockout
and knock-in models of Dravet (Yu et al., 2006; Ogiwara et al., 2007;
Oakley et al., 2011; Yamakawa, 2011, Kalume et al., 2013; Liautard et
al., 2013,Martin et al., 2010)which share themajor phenotypic features
of the syndrome, including reduced Scn1a expression, seizure onset in
early development, increased susceptibility to heat induced seizures, in-
creased mortality with a sharp peak in early development, and reduced
interneuron excitability. In Scn1aE1099X/+ heterozygous mice, Scn1a
mRNA levels in most brain regions were approximately 50% of wild-
type (WT) controls (Fig. 7b). When continuously EEG-monitored from
postnatal week (PW) 7 to PW11, approximately 80% of the Scn1a-
E1099X/+ mice demonstrated spontaneous seizures with the frequency
of 0.9±0.2 per day. Example of an EEG recording of a typical seizure ep-
isode with post-ictal EEG suppression, frequently observed in Dravet
(Kim et al., 2014), is shown in Fig. 7c, video in Supplementary File 3. Sei-
zures occurred during light and dark periods of the day with equal fre-
quency (Fig. 8). Heat-induced seizure thresholds of Scn1aE1099X/+
mice were signiﬁcantly lower than those of WT mice (see data
below). Similar to Dravet patients and other mouse models, high
death rate was observed during a short period in early development
(PW3–5 in case of the Scn1aE1099X/+ mice), after which mortalityd
a) orWT (b)mice were treated with 4 weekly injections of CUR-1901 at 20 μg/injection or
bility vs core body temperature for WT and Scn1aE1099X/+ transgenic mice treated with
tra of normal EEG (red trace), inter-ictal EEG (green trace), ictal EEG (blue trace) and post-
. ** — p b 0.01.
Fig. 10.Normalization of neuronal activity inDravetmice after CUR-1901 treatment.WT and Scn1a E1099X/+micewere treatedwith a single IT injection of 5 μg of CUR-1901 or saline. (a)
Representative traces of current clamp experiments in hippocampal parvalbumin-positive interneuron in WT and control Scn1a E1099X/+ mice (Het), compared to Scn1a E1099X/+
treated (Het_1901) mice. (b) Input/output function for (a). (c–i) Characteristics of hippocampal parvalbumin-positive neurons (n = 6.5.8 respectively): (c) half-width of action
potential (AP); (d) rise slope of AP; (e) decay slope of AP; (f) amplitude of AP; (g) afterhyperpolarization (AHP) amplitude of AP; (h) input resistance; (i) resting potential (t-test with
correction, p N 0.05). Mean ± S.E.M., * — p b 0.05, ** — p b 0.01.
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33.4% to PW7, and 31.9% to PW10, while in WT mice 97% survived to
PW10. The peak in mortality observed in Dravet mice may be related
to the developmentally regulated decrease in Scn3a coinciding with in-
crease in Scn1a expression (Cheah et al., 2013). Compared to WT, the
Scn1aE1099X/+mice had reduced interneuron excitability and altered
action potential characteristics (see data below).
3.6. Increasing Scn1a in Adult Dravet Mice Improves Spontaneous Seizure
Phenotype
To study the effects of SCN1A upregulation, seven week old Scn1a-
E1099X/+ mice were injected intrathecally (IT) in the lumbar spine with
different doses (5 and 20 μg) of a mouse-speciﬁc AntagoNAT CUR-
1901, once weekly for 4 weeks. Mice were monitored by EEG and
video recording 24 h a day continuously throughout the 28-day treat-
ment period. Frequency and severity of seizures was assessed using
combined EEG and video recording data. After the 4-week treatment
with CUR-1901 or saline, a dose-dependent increase of 10–30% in
Scn1a mRNA levels was observed in the brain of AntagoNAT-treated
Scn1aE1099X/+ mice compared to control (n = 16 for control, n =
8.10 for CUR-1901, ANOVA p = 0.05, Fig. 8a). A similar upregulation
of Scn1a was observed in AntagoNAT-treated WT mice (Fig. 8b). Fur-
thermore, AntagoNAT treatment was associated with dose-dependent
decline in average seizure number in Dravet mice (70% at 20 μg/injec-
tion, Fig. 8c–e). The average number of seizures in vehicle-treated
mice over this period was 0.93/day (ranging from 0.15/day to 2.29/
day). In mice treated with 20 μg/injection of AntagoNAT it was 0.26/
day (ranging from 0/day to 0.92/day, Fig. 8d). Seizure number was
equally reduced during light and dark periods of the day (n = 10/Table 5
SCN1A mutation types in cultured Dravet ﬁbroblasts.
Patient ID
10
D-01
D-02
D-03
D-04
Table 4
Properties of hippocampal parvalbumin-positive interneurons (PVINs).a
Parameter WT
Input resistance (MΩ) 161.2 ± 13.7
Resting potential (mV) −60.12 ± 4.5
Half width (ms) 1 ± 0.05
a Data from dentate gyrus PVINs of WT (n= 7), Scn1aE1099X/+ (n= 5), 1901-treated Scn1agroup, t-test p b 0.05, Fig. 8c). The duration of the few seizures that oc-
curred in AntagoNAT-treated animals during treatmentweek 4was sig-
niﬁcantly decreased (Fig. 8f). The amplitude of ictal and post-ictal
phases during the light periods was signiﬁcantly decreased in CUR-
1901-treated mice compared to controls, and a downward trend was
observed during dark periods (n = 5 in AntagoNAT-treated group,
n= 6 in control, p b 0.05, Fig. 8g, h). Amplitude reduction in post-ictal
state may be due to neuropeptide-induced decrease in neuronal excit-
ability (see RNAseq data above). By treatment week four, 50% of sei-
zures in AntagoNAT-treated mice and 36% of seizures in saline-treated
mice were below stage 5, however this difference was not statistically
signiﬁcant (Fisher exact test p= 0.305). Importantly, multiple-regres-
sion analysis of data from Scn1aE1099X/+ mice showed that 66% of the
variation in seizure frequency could be explained by differences in
Scn1a levels (p = 0.02; n = 23; Table 3). The ﬁnding of positive and
negative correlations between seizure number and Scn1a levels in dif-
ferent brain regions including hippocampus, occipital and parietal corti-
ces, is consistent with the network-based mechanism of seizure
generation in Dravet and likely reﬂects the important but differential
roles played by these regions in seizure generation. WT mice treated
with an active AntagoNAT or saline vehicle did not show any behavioral
manifestations of seizures.
Taken together, these experiments demonstrated that AntagoNAT-
mediated increase of Scn1a in adult Dravetmice (Scn1aE1099X/+) can im-
prove spontaneous seizure phenotype.
3.7. Upregulation of Scn1a Reduces Sensitivity to Heat-induced Seizures
Fever-induced seizures are frequently the ﬁrst manifestation of
Dravet syndrome. Correspondingly, in Scn1aE1099X/+mice heat-inducedMutation type
Codon change GAAtoTAA (glutamate to stop) at residue 1099
Codon change CtoT (threonine to isoleucine) at residue 367
Deletion T at position 1209 (frame shift)
Codon change TtoG (leucine to arginine) at residue 1359
Duplication (cgacacgg) at positions 1844–1845 (truncated protein)
Scn1aE1099X/+ CUR-1901-treated Scn1aE1099X/+
141.7 ± 27.4 117.2 ± 12.6
−54.49 ± 2.2 −57.62 ± 3.6
1.7 ± 0.27 0.9 ± 0.14
E1099X/+ (n= 8) mice.
Fig. 11.Upregulation of SCN1A expression after AntagoNAT treatment of different Dravetmutations. (a) SCN1AmRNA levels in 5Dravet patientﬁbroblast lines treatedwith 20 nMof CUR-
1916; normalized to inactive oligonucleotide control, real time PCR data, t-test with Bonferroni correction, n = 18/group. (b) Copy numbers of WT and mutant (X) SCN1A mRNAs in
ﬁbroblast lines D-00 and D-02. Mutant mRNA was undetectable in both cell lines (allele-speciﬁc real time PCR with synthetic copy number standards, n = 3 wells/group). Mean ±
S.E.M., ** — p b 0.01, *** — p b 0.001.
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0.3 °C and 43.2±0.1 °C respectively). To test if increasing Scn1a expres-
sion after birth can affect the heat-induced seizure threshold, we intra-
thecally injected 7 week-old Scn1aE1099X/+ mice weekly with 1 μg of
CUR-1901, or an equal volume of saline, for 4weeks. The heat induction
test was conducted 3 days after the last injection. Seizure threshold tem-
perature in CUR-1901-treatedmicewas signiﬁcantly increased compared
to vehicle controls (41.42 ± 0.26 and 40.15 ± 0.27, n= 4 and n= 6 re-
spectively, t-test p=0.01, Fig. 9). Threshold temperatures inWTmice did
not change signiﬁcantly after AntagoNAT treatment compared to vehicle-
treated mice (43.6 ± 0.16 °C and 43.8 ± 0.1 °C respectively, Fig. 9b).Fig. 12.AntagoNATdistribution and Scn1a upregulation in vivo inAfrican greenmonkeys. Anima
in monkey brain 7 days after injection (hybridization assay data). (b) CUR-1916 concentra
(hybridization assay data, n = 9). (c–f) Upregulation of Scn1a mRNA in brain regions (n = 6
p b 0.05). (g) Correlation of CUR-1916 concentration in tissues with Scn1a upregulation lev
treated with 0.04 mg/kg of CUR-1916 (ANOVA p N 0.1, n = 6/group). (i–k) Scn1a mRNA exp
oligonucleotide CUR-1462 (normalized to saline control, ANOVA p = 0.21, n = 7 for CUR-1
ANOVA p=0.05, n=4); (k) human-speciﬁc AntagoNAT CUR-1945 (normalized to CUR-1462, AOverall, these results indicate that increasing Scn1a expression in adult
Dravet mice can reduce sensitivity to heat-induced seizures.
3.8. Upregulation of Scn1a in Dravet Mice Normalizes Excitability of
Parvalbumin Interneurons
In previous mouse models of Dravet, seizure phenotype correlated
with reduced excitability in hippocampal interneurons (Mistry et al.,
2014; Tai et al., 2014; Cheah et al., 2012). To determine if upregulated
Scn1a expression observed in our experiments affects neuronal excit-
ability, we investigated ﬁring characteristics of parvalbumin (PV)-lswere injected ITwith different doses of CUR-1916. (a) Tissue concentration of CUR-1916
tions in different monkey brain regions after treatment with 0.04 mg/kg of CUR-1916
for 0.008 mg/kg, n = 9 for 0 and 0.04 mg/kg of CUR-1916; real time PCR data, ANOVA
els (regression p = 0.02). (h) Scn1a expression levels in peripheral organs in monkeys
ression levels in CNS regions of monkeys treated IT with 0.04 mg/kg of: (i) an inactive
462, 9 for saline); (j) human-speciﬁc AntagoNAT CUR-1740 (normalized to CUR-1462,
NOVA p=0.1, n=4).Mean± S.E.M., *— p b 0.05, #— p b 0.1.Mean± S.E.M., *— p b 0.05.
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AntagoNAT-treated and control Scn1aE1099X/+ mice. PV-positive inter-
neurons were recognized by their large soma (N30 μm), fast spiking
and localization at the border of the granule cell layer in the dentate
gyrus (DG), and later conﬁrmed by IHC staining for PV. The activity of
PV-positive interneurons was recorded under current clamp in 5–
6 week old mice, 4 days after a single IT injection of 5 μg of CUR-1901.
Compared to WT, the Scn1aE1099X/+ control mice had higher current
threshold to ﬁrst action potential (AP) and impaired AP ﬁring frequen-
cies (Fig. 10a, b). These deﬁcits were signiﬁcantly improved after CUR-
1901 treatment, with both AP ﬁring threshold and ﬁring frequency re-
stored to values approachingWT (Fig. 10a, b). Furthermore, AP charac-
teristics which were signiﬁcantly altered in Dravet mice, including AP
half-width, rise slope, decay slope and amplitude, returned toWT levels
after treatment with AntagoNAT, with decay slope and amplitude
slightly exceeding WT values (Fig. 10c-f). Decreased amplitude of
afterhyperpolarization (AHP) observed in Scn1aE1099X/+ mice com-
pared to WT, was not affected by the AntagoNAT treatment (Fig. 10g).
This could be explained by the short duration of the experiment
(78 h), not sufﬁcient to alter the adaptive changes in BK channels,
which are themajor contributors to AHP. Our RNAseq data also showed
that short-term Scn1a upregulationwas not accompanied by changes in
expression of BK channel subunits (Supplementary File 1). Input resis-
tance and resting potential were not signiﬁcantly altered in any group
(Fig. 10h, i; Table 4).
Taken together, these data indicate that increasing Scn1a expression
in adult mice is associated with improved electrophysiological charac-
teristics of PV-positive hippocampal interneurons, which are essential
for the pathophysiology of Dravet.
3.9. AntagoNAT Treatment Upregulates SCN1A in Cells With Diverse Dravet
Mutations
Dravet syndrome is caused by a wide variety of de novo mutations,
which are rarely inherited. To determine if same AntagoNAT can upreg-
ulate SCN1A in cells with different mutation types, we treated primary
ﬁbroblasts from 5 patients with 20 nM of a human-speciﬁc AntagoNAT
CUR-1916 or an inactive control oligonucleotide of similar chemistry.
Mutation types were nonsense, missense, frame shift and short duplica-
tion (Table 5). In all ﬁbroblast lines SCN1AmRNA levels were increased
after AntagoNAT treatment by at least 10 fold, and up to 40 fold, com-
pared to control (real time PCR data, ANOVA p N 0.001, n= 18/group,
Fig. 11a). Notably, the D-02 line, showing the highest upregulation of
SCN1A upon AntagoNAT treatment, had a much lower basal SCN1A
level compared to D-00 line (Fig. 11b). Using allele-speciﬁc gene-ex-
pression assays with synthetic calibration standards we determined
that mutant SCN1A mRNA was not detectable in either D-00 or D-02
line (Fig. 11b).
Overall, these results indicate that AntagoNAT-mediated inhibition
of SCN1ANAT results in the upregulation of SCN1A regardless of the
SCN1A mutation type, thus increasing potential applicability of the
AntagoNATmethod in the treatment of Dravet syndrome and other dis-
eases caused by de-novo mutations.
3.10. Intrathecal Injection of Human AntagoNATs Upregulates Scn1a in
Non-human Primate Brain
Asmouse and human SCN1ANATs do not share signiﬁcant sequence
similarity, we had to use mouse-speciﬁc AntagoNATs in our experi-
ments in Dravet mice. To determine if their human-speciﬁc counter-
parts would have the same effect on Scn1a expression in vivo, we
employed African green monkey model, whose Scn1aNAT is highly ho-
mologous to human (Table 1). Furthermore, human-speciﬁc
AntagoNATs induced gene-speciﬁc Scn1a mRNA and protein upregula-
tion in an African green monkey cell line Vero76 (Figs. 4b, 5h). Besides
species-speciﬁcity, other issue that could be addressed in the Africangreenmonkeymodelwas absorption, distribution and cellular availabil-
ity and safety of AntagoNATs after IT administration, because CNS anat-
omy and physiology of non-human primates closely resembles human.
We injected African greenmonkeys once ITwith saline vehicle, inac-
tive control oligonucleotide or active primate-speciﬁc AntagoNATs at 1,
0.2, 0.04 or 0.008mg/kg doses. The animals were sacriﬁced 1week after
injection. The resulting tissue concentrations of AntagoNAT CUR-1916
varied depending on injected amount, exposure to CSF circulation and
proximity to injection site (Fig. 12a, b). Seven days after injection of
0.008 and 0.04 mg/kg doses, concentrations of the full length CUR-
1916 were 45% and 16%, respectively, of the maximum possible assum-
ing even distribution of AntagoNAT over CNS volume. AntagoNAT con-
centrations in the CSF seven days after injection were 5.27 ± 1.99 ng/
ml at the 0.008 mg/kg dose and 16.79 ± 4.12 ng/ml at 0.04 mg/kg
(n = 6). In plasma after 7 days CUR-1916 was undetectable at doses
below 1 mg/kg, where it equaled 0.15 ± 0.05 ng/ml (n = 3). CUR-
1916 was also undetectable in peripheral organs including heart, lung
and spleen, at and below0.2mg/kg (n=9). In kidney the concentration
was below quantitation limit at 0.008 mg/kg (n = 6) and 0.04 mg/kg
(n= 9); at 0.2 and 1 mg/kg it was 0.27 ± 0.04 and 0.34 ± 0.05 ng/mg
tissue respectively (n = 3). Confocal microscopy demonstrated that
CUR-1916 was present inside hippocampal parvalbumin-positive neu-
rons, which are central to Dravet pathogenesis (video in Supplementary
File 4).
Brain Scn1a mRNA levels measured seven days after IT injection of
CUR-1916 were upregulated in dose-dependent fashion compared to
vehicle and inactive oligonucleotide controls, with the largest increase
observed in ependyma (250%, ANOVA p b 0.05; Fig. 12c-f). The average
levels of Scn1a upregulation in brain regions followed theobserved local
AntagoNAT concentration with EC50 of approximately 0.22 ng CUR-
1916/mg tissue (r2 = 0.43, p = 0.01; Fig. 12g). In peripheral tissues
no signiﬁcant effect of AntagoNAT treatment on Scn1a mRNA levels
was observed (ANOVA p N 0.1; Fig. 12h). To conﬁrm that AntagoNAT ef-
fect was target-speciﬁc,we treatedmonkeys ITwith 0.04mg/kg of CUR-
1740 or CUR-1945 (active AntagoNATswith different chemistry and se-
quences) or CUR-1462 (an inactive oligonucleotide). While Scn1a ex-
pression after treatment with CUR-1462 did not differ from vehicle
control (ANOVA p=0.21,n=3/group), the active AntagoNATs induced
statistically signiﬁcant upregulation, or upregulation trends in Scn1a ex-
pression (+15 to +60%; n= 3/group, Fig. 12i–k).
Histopathological examination of brains of animals one week after
treatmentwith different doses of CUR-1916 revealed noAntagoNAT-as-
sociated histopathology.
Overall, the experiments in African green monkeys indicate that
human AntagoNATs injected IT in saline vehicle can induce speciﬁc
Scn1a upregulation in vivo in a CNS closely resembling human. The ex-
periments also demonstrate that AntagoNATs injected IT are largely safe
and contained within CNS, reducing the possibility of peripheral side
effects.
4. Discussion
At present time the majority of genetic disorders involving
haploinsufﬁciency in a single gene, such as Dravet syndrome, have no
adequate treatment. Only partially effective symptomatic therapy
targeted at seizure reduction is now available for Dravet patients. Fur-
thermore, although initially Dravet syndrome was considered an epi-
leptic encephalopathy (Wolff et al., 2006), recent studies in Dravet
patients have shown that some aspects of the syndromemay arise inde-
pendently of seizures and thus cannot be addressed by anticonvulsants
(Nabbout et al., 2013). In rat models, siRNA-mediated Scn1a knock-
down in adult animals selective for basal forebrain induced cognitive
impairment without seizures (Bender et al., 2013). Notably, upregula-
tion of the remaining normal copy of the damaged gene has the poten-
tial to improve all disease manifestations and represents an appealing
therapeutic strategy.
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of SCN1A expression, mediated by a gene-speciﬁc NAT, and showed
that blocking this NAT can be used to achieve speciﬁc SCN1A upregula-
tion in cells, including cells heterozygous for Dravet mutations. These
results indicate that NAT-mediated regulation is not engaged, or at
least not tapped out, in haploinsufﬁcient cells, possibly due to lack of
the feedback from SCN1A protein levels. NAT-mediated expression con-
trol is present in many disease-relevant loci and can potentially be used
in the treatment of multiple haploinsufﬁciency-linked genetic disorders
and other diseases where upregulation of disease-causing gene can be
beneﬁcial.
In our in vitro and in vivo experiments we were able to upregulate
SCN1A expression by using AntagoNATs (oligonucleotide-like com-
pounds) that block the activity of SCN1ANAT. While AntagoNAT treat-
ment upregulated SCN1A, it did not affect N90% of all expressed genes,
including other highly homologous sodium channel subunits and
genes immediately adjacent to SCN1A on the chromosome (Fig. 5; Sup-
plementary File 1).
Furthermore, we have demonstrated that SCN1A upregulation can
be effective in a mouse model of Dravet if applied at some time point
after birth, when genetic disorders are usually diagnosed. Our experi-
ments in a mouse model harboring a known Dravet mutation demon-
strate that Scn1a upregulation during PW 7–11 leads to
improvements in several aspects of disease phenotype, including fre-
quency and severity of seizures. We observed that a 25% increase in
brain Scn1a levels was sufﬁcient to elicit a 70% reduction in seizure fre-
quency and a decrease in seizure severity (Fig. 8). Additionally, upregu-
lation of brain Scn1a levels was associated with decreased sensitivity to
heat-induced seizures, which represent a hallmark of Dravet syndrome.
AntagoNAT treatment also normalized increased ﬁring threshold and
reduced ﬁring frequency of inhibitory interneurons observed in Dravet
models (Fig. 9, Oakley et al., 2011; Yamakawa, 2011; Tai et al., 2014;
Ogiwara et al., 2013). Importantly, in rat models with RNAi-induced
Scn1a knockdown, disruption in neuronal ﬁring was correlated with
performance in workingmemory task (Bender et al., 2016). This under-
scores the importance of normalizing the neuronal ﬁring for the treat-
ment of cognitive deﬁcits associated with Dravet syndrome. Overall,
signiﬁcant improvements of seizure phenotype and neuronal electro-
physiology observed in our experiments provide an integral indicator
that Scn1a upregulation achieved using AntagoNATs can adequately ad-
dress the excitation/inhibition imbalance occurring in Dravet brain.
Besides seizures, another known aspect of Dravet syndrome is in-
creased mortality (Dravet, 2011). Similar to human disease, the death
rate in the Scn1aE1099X/+ mice peaks in early development (with ap-
proximately 70% of mice dying before PW7) and then stabilizes at rela-
tively low levels. Additionally, Dravet mice are generally smaller and
have elevated sensitivity to surgical interventions compared to
WT. For these reasons, in our experiments EEG electrode implantation
and IT injection of AntagoNATs were conducted at PW7–11, past the
critical period. As a result, the small numbers of deaths observed in
our studies did not allow for a conclusive statistical analysis at this
time. Consequently, the reported results are only relevant to the more
mildly affected surviving mice or potentially Dravet patients older
than 3 years. Further experiments, in which AntagoNAT treatment will
be started prior to the PW3–5 critical window are needed to verify
whether AntagoNAT-mediated upregulation of SCN1A could reduce
the early mortality rate. Due to technical difﬁculties, these experiments
would likely require development of an alternative administration
route.
Further experiments are underway to test if the increase in Scn1a
levels in a Dravet mouse model would affect other Dravet manifesta-
tions, such as delayed psychomotor development and autistic-like be-
havior. Taken together, our results demonstrate that at least some of
the major aspects of Dravet are likely to be caused by persistent
SCN1A deﬁcit after birth and can be improved by AntagoNAT-mediated
upregulation of SCN1A.Additionally, we showed that treatment with the same AntagoNAT
induced SCN1A upregulation in human cells with different mutation
types (Fig. 11), thus opening the possibility of using one AntagoNAT
for the treatment of many Dravet patients, as opposed to designing a
separatemolecule for eachmutation. This aspect is particularly relevant
in Dravet syndrome, which is usually caused by de novomutations. Fur-
thermore, the cost of the initial screening of AntagoNATs is substantially
lower compared to small molecules, which makes AntagoNATs highly
amenable for the treatment of genetic disorders will small patient
populations.
Given the signiﬁcant differences in the anatomy and physiology of
human and rodent CNS and the diversity in the sequences of human
and mouse SCN1ANATs, we also tested the effects of human-speciﬁc
AntagoNATs in a non-human primate model (Fig. 12). Primates have
high SCN1ANAT sequence conservation and their CNS anatomy and
physiology closely resembles human. A single IT injection of the
human-speciﬁc AntagoNAT CUR-1916 in saline vehicle induced dose-
dependent increase of Scn1a expression in the brain of African green
monkeys (Fig. 12c–f). At the same time, we observed intracellular local-
ization of AntagoNATs inside hippocampal parvalbumin positive neu-
rons, which are essential to Dravet pathophysiology and represent an
important cellular target for therapeutic upregulation of SCN1A (video
in Supplementary File 4). The observed sequestration of AntagoNATs
in the CNS after IT administration will likely reduce the possibility of
side effects in peripheral organs. Additionally, the in vivo doses of
AntagoNATs which induced signiﬁcant upregulation of Scn1a in our ex-
periments were approximately 10-fold lower than active doses report-
ed for oligonucleotides with other mechanisms of action (Miller et al.,
2013; Flanigan et al., 2014). Using lower doses would further reduce
the chances of adverse events. Taken together these results indicate
that IT administration of AntagoNATsmay be a viable route for upregu-
lating SCN1A expression in the clinic.
5. Conclusions
Overall, our results show that gene upregulation through blocking
the inhibitory activity of NATs by AntagoNAT treatment may improve
several aspects of Dravet syndrome. Furthermore we demonstrate that
IT injection in a saline vehicle is safe and represents a viable administra-
tion route for AntagoNATs in the clinic. As large proportion of protein
loci are regulated by NATs, NAT-targeted therapies can be applied in
many currently untreatable human genetic disorders associated with
haploinsufﬁciency and other diseases which can beneﬁt from gene
upregulation.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.05.011.
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